Blog - QualityStocks

MondayJul 27, 2026 3:26 pm

QualityStocksNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Executive Outlines Lucid-MS Development Strategy and Commercial Growth Plans

Disseminated on behalf of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM), a biopharmaceutical company focused on advancing innovative therapies and technologies, was featured in a recent episode of the BioMedWire Podcast. During the program, Executive Co-Chairman and Co-Founder Anthony Durkacz discussed the company’s strategy for advancing Lucid-MS, its lead drug candidate for multiple sclerosis, as well as the commercial opportunity surrounding its unbuzzd product. Durkacz highlighted Lucid-MS’s goal of addressing mobility damage associated with MS and noted that the company has filed an investigational new drug application for a Phase 2 clinical trial,…

MondayJul 27, 2026 2:53 pm

QualityStocksNewsBreaks – Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) Moves Lead Oncology Candidate Toward Future Clinical Studies

Disseminated on behalf of Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) and may include paid advertising. Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) is advancing the development of its lead oncology candidate, ONC010, a PNKP inhibitor designed to disrupt cancer cells’ DNA repair mechanisms and potentially address treatment resistance. The company recently advanced kilogram-scale manufacturing of a key precursor used to produce ONC010’s active pharmaceutical ingredient, supporting future formulation development, GMP production and clinical studies. Onco-Innovations also signed a letter of intent with Nanosoft Polymers to advance polymer development, drug delivery optimization and formulation work, while engagements with Nucro-Technics and Avance Clinical support bioanalytical development and clinical…

MondayJul 27, 2026 2:49 pm

QualityStocksNewsBreaks – Datavault AI Inc. (NASDAQ: DVLT) Advances NIL Debit Card Initiative, Names Ronald Goldstein to Lead Sports Licensing

Datavault AI (NASDAQ: DVLT) announced progress on its NIL debit card capability through its embedded banking and payments arrangement with Fiserv while appointing Ronald M. Goldstein to lead professional sports licensing for its NIL Vault ("NILv") platform. The company said the planned payment wallets and debit cards are intended to enable participating athletes to receive, manage and access funds earned through sponsorship and NIL activities. Datavault AI said Goldstein, who has more than 35 years of experience in sports marketing, licensing, intellectual property and commercial partnerships, has already begun advancing official licensing initiatives for NIL Vault, including programs involving Josh Gibson, Roberto Clemente and…

MondayJul 27, 2026 2:28 pm

QualityStocksNewsBreaks – Datavault AI Inc. (NASDAQ: DVLT) Names Dwight Gooden NILX Brand Ambassador

Datavault AI (NASDAQ: DVLT) announced that former Major League Baseball pitcher Dwight "Doc" Gooden has signed as a brand ambassador for Datavault NILX, the company's name, image and likeness ("NIL") exchange platform. Under the agreement, Gooden will produce at least 10 original videos, participate in promotional activities and receive a share of revenue generated by his content, while Datavault AI will provide platform support, activity tracking, attribution and payment administration. The company said NILX is designed to enable athletes and other public figures to monetize and maintain an ongoing stake in the value generated by their name, image and likeness through measurable and auditable engagement. Gooden joins the platform ahead of its commercial launch as Datavault AI continues expanding its portfolio…

MondayJul 27, 2026 2:15 pm

QualityStocksNewsBreaks – Earth Science Tech Inc. (ETST) Builds on End-to-End Platform Connecting Telemedicine, Pharmacy and Fulfillment

Earth Science Tech (OTC: ETST) recently announced fiscal year 2026 results for the year ended March 31, 2026, highlighting growth across key financial metrics as it continues to operate its diversified holdings model spanning healthcare, pharmaceuticals, telemedicine, real estate and consumer businesses. Revenue increased 8% to $35.7 million, gross profit rose 5% to $25.5 million, net income grew 11% to $3.6 million, and total assets increased 27% to $9 million. CEO Giorgio R. Saumat attributed the results to ETST’s efforts to fully integrate the patient experience across telemedicine to pharmacy to fulfillment. To view the full article, visit https://ibn.fm/mY8eX About Earth Science Tech…

MondayJul 27, 2026 12:16 pm

QualityStocksNewsBreaks – MAX Power Mining Corp. (CSE: MAXX; OTC: MAXXF; FRANKFURT: 89N) Reports Encouraging Progress at Lawson Natural Hydrogen Well

This article has been disseminated on behalf of MAX Power Mining and may include paid advertising. MAX Power Mining (CSE: MAXX; OTC: MAXXF; FRANKFURT: 89N) provided an update on drilling at its Lawson 2 well in Saskatchewan, the first in a multi-well commercial validation program at Canada's first confirmed subsurface natural hydrogen system. The company said drilling has reached a measured depth of 2,370 meters, where it paused ahead of a second coring phase after encountering a natural hydrogen-rich fracture zone in the basement complex. Management reported that hydrogen readings have been stronger and more continuous than those recorded at the original Lawson discovery well, while helium spikes and geological observations…

MondayJul 27, 2026 11:58 am

QualityStocksNewsBreaks – American Fusion Inc. (OTC: AMFN) Highlights Texatron(TM) Technology at APS Particle Physics Conference

American Fusion (OTC: AMFN) announced that Chief Technology Officer Dr. John E. Brandenburg presented the company's Texatron(TM) Fusion Engine(TM) technology and his Gravity-Electromagnetic ("GEM") Unification Theory at the American Physical Society Division of Particles and Fields 2026 Meeting held at the U.S. Department of Energy's Fermilab. The presentation outlined the GEM framework, which proposes a first-principles mathematical derivation of Newton's gravitational constant and integrates concepts from gravity, electromagnetism, plasma physics and quantum mechanics. The company said the theoretical work complements its ongoing research into plasma behavior and controlled fusion, although the GEM theory remains subject to continued scientific evaluation. American Fusion also noted strong audience engagement during…

MondayJul 27, 2026 11:46 am

QualityStocksNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Shareholders Approve Corporate Governance, Financing Measures

VERAXA Biotech (NASDAQ: VRXA) announced that shareholders overwhelmingly approved all proposals presented at its Extraordinary General Meeting, with more than 99.94% of votes cast in favor and 72.20% of the company's outstanding share capital represented. The approved measures include the introduction of conditional share capital for shareholder options and warrants, implementation of a capital band through Dec. 31, 2030 and an increase in the maximum size of the board of directors from five to seven members. The company said the enhanced corporate and financing framework is intended to support its long-term growth strategy by providing greater flexibility for potential acquisitions, strategic collaborations, investment projects, capital…

MondayJul 27, 2026 11:31 am

QualityStocksNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Advances Bispecific ADC Program Under OmniAb Collaboration

VERAXA Biotech (NASDAQ: VRXA) announced the advancement of its bispecific antibody-drug conjugate ("bsADC") program, VXA-222, after reaching a key technical milestone in its collaboration with OmniAb (NASDAQ: OABI). The company said OmniAb has successfully completed its discovery work, allowing the program to move into its next phase. VXA-222 is designed to target two tumor antigens with a single molecule using an "AND-gate" approach intended to improve precision in treating solid tumors. Under the collaboration launched in May 2025, OmniAb provided antibody discovery technologies, including its OmniClic(TM) platform, while VERAXA is applying its proprietary linker technology and conjugation expertise to develop and validate the lead bsADC candidate. VERAXA holds exclusive rights to develop and commercialize…

MondayJul 27, 2026 10:30 am

Wrap Technologies Inc. (NASDAQ: WRAP) Brings Remote Restraint Innovation and Emerging Detection Technology to Modern Public Safety

Pressure on agencies to adopt response-to-resistance alternatives has intensified, widening demand for tools that can control situations without injury or pain rather than provoke confrontations. Wrap has built its business around a Non-Lethal Response(TM) platform that converges remote restraint, training, and evidence management, spanning the BolaWrap(R) 150, Wrap Reality(TM), Wrap Vision(TM), Wrap Tactics(TM), and counter-drone solutions. With the July 2026 launch of WrapShield(TM) and an exclusive U.S. and NATO license to Frenel Imaging’s TPiCore(R) thermal-polarimetric sensing, Wrap is adding an AI-enabled detection layer, beginning with counter-UAS. A Widening Market for Response-to-Resistance Technology High-profile use-of-force incidents have driven costly litigation, strained…

Site Search

Company Search